In Segment A, participants will obtain different doses and schedules of oral ABBV-744 tablet to establish Secure dosing routine. Additional individuals might be enrolled in the determined monotherapy dosign program. In Segment B, participants will obtain oral ruxolitinib and ABBV-744 are going to be offered as "incorporate-on" therapy. In Phase https://chanceznamf.blogolenta.com/28904669/not-known-details-about-brd4-inhibition-by-abbv-744-in-cancer-research-studies